Abstract

BACKGROUND:

Evening sweats substantially influence the good quality of life for cancer patients and are normally resistant to therapy. Cannabinoids have been shown to modulate cytokine activity and make hypothermia in animal models, suggesting that they might be a promising candidate for palliation of evening sweats in individuals with oncologic illness.

OBJECTIVE:

Assess efficacy of the oral cannabinoid, dronabinol, for palliation of evening sweats in cancer patients.

Design and style:

A retrospective record search identified five cancer patients who had attempted oral dronabinol for palliation of their evening sweats amongst 2013 and 2016 and subjectively reported on its efficacy.

SETTING/SUBJECTS:

A comfort sample of 5 individuals from the outpatient consultative palliative medicine system at Stanford Health-related Center was selected from a search of previous records. Sufferers have been incorporated if they had a cancer diagnosis and complained of evening sweats that subjectively interfered with their good quality of life. All agreed to attempt oral dronabinol for palliation of their evening sweats.

MEASUREMENTS:

Sufferers self-reported the impact of oral synthetic dronabinol on their evening sweats.

Final results:

Remedy of 5 individuals with advanced cancer with synthetic orally administered dronabinol resulted in the productive management of persistent symptomatic paraneoplastic evening sweats.

CONCLUSION:

Dronabinol and/or medicinal  cannabis are promising therapies for palliation of evening sweats in cancer patients.

Copyright © 2018 Elsevier B.V. All rights reserved.

 

Supply:Pubmed

 

 

PMID: 30759037 DOI: 10.1089/jpm.2018.0551

Carr C1, Vertelney Htwo, Fronk Jthree, Trieu Sfour.